Clinical trial · Observational
QSM and Regional DCE MRI Permeability Using GOCART Technique
Evaluation of Regional Gadolinium Retention in the Brain Using QSM With Correlation to Regional DCE MRI Permeability Using GOCART Technique in Intracranial Neoplasm Patients Receiving Gadobenate Dimeglumine (MultiHance) or Gadoterate Meglumine (Dotarem)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): No accrual
Summary
Brief summary (as posted)
This randomized pilot clinical trial studies quantitative susceptibility mapping (QSM) and regional dynamic contrast enhanced (DCE) magnetic resonance imaging (MRI) permeability using golden-angle cartesian randomized time-resolved (GOCART) technique in evaluating regional gadolinium retention in the brain in patients with intracranial neoplasm receiving gadobenate dimeglumine or gadoterate meglumine. MRI diagnostic techniques such as, QSM and DCE MRI, may help to gather information regarding brain changes associated with gadolinium deposits during 8 to 18 months after administration of gadobenate dimeglumine or gadoterate meglumine.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Intracranial Neoplasm | Intracranial Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Dynamic Contrast-Enhanced Magnetic Resonance Imaging | Device | — | UNRESOLVED |
| Gadobenate Dimeglumine | Drug | — | UNRESOLVED |
| Gadoterate Meglumine | Drug | — | UNRESOLVED |
| Magnetic Resonance Imaging | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Arm I (QSM, T1WI, gadobenate dimeglumine, GOCART DCE MRI)
- description
- Patients undergo standard of care QSM and T1WI. Patients then receive gadobenate dimeglumine IV and undergo GOCART DCE MRI over 60 minutes.
- interventionNames
- Device: Dynamic Contrast-Enhanced Magnetic Resonance Imaging
- Drug: Gadobenate Dimeglumine
- Device: Magnetic Resonance Imaging
- label
- Arm II (QSM, T1WI, gadoterate meglumine, GOCART DCE MRI)
- description
- Patients undergo standard of care QSM and T1WI. Patients then receive gadoterate meglumine IV and undergo GOCART DCE MRI over 60 minutes.
- interventionNames
- Device: Dynamic Contrast-Enhanced Magnetic Resonance Imaging
- Drug: Gadoterate Meglumine
- Device: Magnetic Resonance Imaging
Primary outcomes (1)
- measure
- Change in QSM score
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patient with suspected intracranial neoplasm scheduled for routine MRI with GBCA (gadolinium naive patients) * Willingness to comply with the study protocol Exclusion Criteria: * Contraindications for MRI or GBCA (standard of care) * Abnormal renal function with estimated glomerular filtration rate (eGFR) less than 30 mL/min/m\^2 based on creatinine obtained within last 30 days * History of previous administration of GBCA
References
Publications (0)
Data not yet available